flufenamic acid | 32621-47-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: flufenamic acid
• 英文别名: Hfluf；N-(2-trifluoromethylphenyl)anthranilic acid；Flufenaminsaeure, N-(3-Trifluormethyl-phenyl)-anthranilsaeure；2-Trifluormethyldiphenylamin-2'-carbonsaeure；N-(2'-Trifluoromethylphenyl)anthranilsaeure；O-Trifluoromethylphenyl anthranilic acid；2-[2-(trifluoromethyl)anilino]benzoic acid
• CAS: 32621-47-9
• 化学式: C₁₄H₁₀F₃NO₂
• 分子量: 281.234
• InChiKey: ONKHJNFXJDEMNQ-UHFFFAOYSA-N

物化性质

• 熔点：
  207-209 °C
• 沸点：
  366.8±42.0 °C(Predicted)
• 密度：
  1.395±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  flufenamic acid 、 二苯基氧化锡 以 not given 为溶剂， 生成
  参考文献：
  名称：

  Recent advances on non-steroidal anti-inflammatory drugs, NSAIDs: Organotin complexes of NSAIDs

  摘要：

  An overview is given of the results of organotin-NSAIDs interactions. Several organotin complexes with NSAIDs, derivatives of the carboxylic acid family and oxicam family, have been synthesized and characterized by spectroscopy and X-ray crystallography at the University of Ioannina. Results concerning the biological activity of these organotin complexes will be referred. (c) 2005 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2005.11.058
• 作为产物：
  描述：

  2-(2-Trifluoromethyl-phenylamino)-benzoic acid methyl ester 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 flufenamic acid
  参考文献：
  名称：

  基于邻氨基苯甲酸的运甲状腺素蛋白淀粉样蛋白原纤维抑制剂的合成和评价。

  摘要：

  合成八个小分子以评估N-取代邻氨基苯甲酸的结构活性关系（SAR）。通过邻氨基苯甲酸甲酯的苄基化或芳基化合成分子。基于光散射的淀粉样蛋白原纤维形成试验用于评估体外转甲状腺素蛋白（TTR）淀粉样蛋白原纤维形成的潜在抑制剂。间羧基苯基化和邻三氟甲基苯基化的邻氨基苯甲酸是有效的抑制剂，将经受进一步的SAR和结构分析。

  DOI：

  10.1016/s0960-894x(98)00696-9

文献信息

• NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME
  申请人：Lee Changjoon Justin

  公开号：US20090131527A1

  公开（公告）日：2009-05-21

  The present invention relates to novel anthranilic acid derivatives represented by Chemical Formula I, and a chloride channel blocking agent containing the anthranilic acid derivative or its pharmacologically acceptable salts as an active ingredient. In another aspect, the present invention relates to a method of accurately and efficiently detecting the intracellular chloride channel inhibition and method of screening a chloride channel blocking agent.

  本发明涉及新颖的由化学式I表示的蒽酰胺衍生物，以及含有该蒽酰胺衍生物或其药理学上可接受的盐作为活性成分的氯通道阻滞剂。在另一个方面，本发明涉及一种准确高效地检测细胞内氯通道抑制和筛选氯通道阻滞剂的方法。
• HIGH PENETRATION COMPOSITIONS AND USES THEREOF
  申请人：Yu Chongxi

  公开号：US20090238763A1

  公开（公告）日：2009-09-24

  The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate.

  本发明涉及新型高渗透性组合物或高渗透性前药（HPP）的组成和用途，特别是用于非甾体抗炎药（NSAIAs）的HPP，其能够高效地穿过生物屏障。这里的HPP能够在穿过生物屏障后转化为父活性药物或药物代谢物，从而可以治疗与父药物或代谢物相关的疾病。此外，由于能够穿过生物屏障，这里的HPP能够到达父药物可能无法进入或无法在目标区域产生足够浓度的区域，从而提供新的治疗方法。这里的HPP可以通过各种给药途径给予受试者。例如，由于其穿透生物屏障的能力，HPP可以在局部给药到疾病作用部位并以高浓度存在，从而避免系统性给药的需要。另一个例子是，这里的HPP可以被系统性地给药到生物体内，并以更快的速率进入循环系统。
• Advanced drug development and manufacturing
  申请人：Los Alamos National Security, LLC

  公开号：EP2511844A2

  公开（公告）日：2012-10-17

  There is described an apparatus for measuring protein characteristics comprising an X-ray fluorescence (XRF) spectrometer comprising a source of polychromatic X-rays, an X-ray detector, a protein, a molecule that has been exposed to and at least weakly binds to the protein, a plurality of X-ray fluorescence signal data obtained by irradiating chemical elements in the protein and molecule with the polychromatic X-rays and a security system for maintaining records for the data from the plurality of X-ray fluorescence signal measurements. There is also described an x-ray microscope for measuring a sample.

  描述了一种测量蛋白质特性的仪器，该仪器包括一个 X 射线荧光 (XRF) 光谱仪，其中包括一个多色 X 射线源、一个 X 射线探测器、一个蛋白质、一个已暴露于该蛋白质并至少与该蛋白质弱结合的分子、通过用多色 X 射线照射蛋白质和分子中的化学元素而获得的多个 X 射线荧光信号数据，以及一个用于维护多个 X 射线荧光信号测量数据记录的安全系统。此外，还介绍了一种用于测量样品的 X 射线显微镜。
• Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate
  申请人：Techfields Biochem Co. Ltd

  公开号：EP2623495A1

  公开（公告）日：2013-08-07

  The novel positively charged pro-drugs of arylanthranilic acids in the general formula (1) 'Structure 1' were designed and synthesized. The compounds of the general formula (1) 'Structure 1' indicated above can be prepared from mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds, by reaction with suitable alcohols, thiols, or amines and coupling reagents, such as N, N'-Dicyclohexylcarbodiimide, N, N'-Diisopropylcarbodiimide, O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, Benzotriazol-1-yl-oxy-tris (dimethylamino)phosphonium hexafluorophosphate, et al. The positively charged amino groups of these pro-drugs not only largely increases the solubility of the drugs, but also bonds to the negative charge on the phosphate head group of membranes and pushes the pro-drug into the cytosol. The results suggest that the pro-drugs diffuses through human skin -200 times faster than does mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds. It takes 2-4 hours for mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds to reach the peak plasma level when they are taken orally, but these prodrugs only took about -50 minutes to reach the peak plasma level when they are taken transdermally. In plasma, more than 90% of these pro-drugs can change back to the parent drugs in a few minutes. The prodrugs can be used medicinally in treating any NSAIAs-treatable conditions in humans or animals. The prodrugs can be administered not only orally, but also transdermally for any kind of medical treatments and thus avoid most of the side effects of NSAIAs, most notably GI disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis. Controlled transdermal administration systems of the prodrug enables mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds to reach constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds. Another great benefit of transdermal administration of these pro-drugs is that administering medication, especially to children, will be much easier.

  设计并合成了通式（1）"结构 1 "中的新型带正电的芳兰二酸原药。上述通式(1)'结构 1'化合物可以由甲灭酸，甲氯灭酸，氟灭酸，硝氟酸，氟尼辛和相关化合物通过与合适的醇、硫醇或胺和偶联试剂（如 N. N'-二环己基碳二亚基）反应制备、N,N'-二环己基碳二亚胺、N,N'-二异丙基碳二亚胺、O-(苯并三唑-1-基)-N,N,N',N'-四甲基脲四氟硼酸盐、O-(苯并三唑-1-基)-N,N,N',N'-四甲基脲六氟磷酸盐、苯并三唑-1-基氧基-三(二甲基氨基)鏻六氟磷酸盐等。这些原药带正电荷的氨基不仅在很大程度上增加了药物的溶解度，还与膜上磷酸头基的负电荷结合，将原药推入细胞质。研究结果表明，原药在人体皮肤中的扩散速度是甲灭酸，甲氯灭酸，氟灭酸，硝氟酸，氟尼辛和相关化合物的 200 倍。口服甲灭酸，甲氯灭酸，氟灭酸，硝氟米酸，氟尼辛和相关化合物需要 2-4 小时才能达到血浆峰值水平，但经皮服用这些原药只需约 -50 分钟就能达到血浆峰值水平。在血浆中，90% 以上的原药可在几分钟内变回母药。这些原药可用于治疗人类或动物的任何非甾体抗炎药物可治疗的疾病。原药不仅可以口服，还可以透皮给药，用于任何类型的医疗，从而避免非甾体抗炎药的大部分副作用，尤其是消化道紊乱，如消化不良、胃十二指肠出血、胃溃疡和胃炎。原药的可控透皮给药系统可使甲灭酸，甲氯灭酸，氟灭酸，硝氟米酸，氟尼辛和相关化合物不断达到最佳治疗血药浓度，从而提高甲灭酸，甲氯灭酸，氟灭酸，硝氟米酸，氟尼辛和相关化合物的疗效并减少其副作用。这些原药透皮给药的另一大好处是，给药，尤其是给儿童给药，将变得更加容易。
• GRABOYES H.; ANDERSON E. L.; LEVINSON S. H.; RESNICK T. M., . HETEROCYCL. CHEM. <JHTC-AD>, 1975, 12, NO 6, 1225-1231
  作者：GRABOYES H.、 ANDERSON E. L.、 LEVINSON S. H.、 RESNICK T. M.

  DOI：——

  日期：——